TSHA Pangali Forward P/E Taysha Corp

Simbol resmi perusahaan Taysha (TSHA)

Taysha Gene Therapies (TSHA) management is currently focusing on adapting clinical programs following personnel changes. The business model relies on the full outsourcing of production and testing to external contractors. The forward P/E ratio history for Taysha Gene Therapies (TSHA) on GURU.Markets reflects valuation dynamics where 0.00 determines this parameter level. High scalability driven by innovative CNS gene delivery promises global reach and massive margins.

TSHA - Pangali Forward P/E Taysha Gene Therapies Inc ing rentang 04.07.2022 - 18.11.2026

TSHA (Taysha Gene Therapies): rincian analitis lan laporan miturut indikator

- nilai saham lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:TSHA Taysha Gene Therapies
Produk merek Taysha Corp

Taysha Gene Therapies develops high-cost treatments for rare CNS pathologies, targeting government healthcare systems. By analyzing the business's forward P/E ratio, an investor sees the relationship between the current share price and expected annual earnings. The value of 0.00 reflects market expectations for future cash flows. This indicator allows one to filter out volatility and assess the risk of overpayment. It is a key tool for the company's fundamental capitalization.

Karo sapa Taysha Gene Therapies saingan

Prakiraan rega marang bathi TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Pangali forward rega marang bathi|Rega marang bathi mangsa ngarep ionispharma.com IONS|Kapitalisasi marang proyeksi bathi Repligen Corporation (RGEN)|RNA: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRSP (CRISPR Therapeutics Corp)|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Pangali Forward P/E|SRPT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Twist Bioscience Corp (TWST)|Prakiraan rega marang bathi 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi STOK|BLFS - Rega marang bathi mangsa ngarep|Wave Life Sciences (WVE) - Prakiraan rega marang bathi|MAZE: Pangali Forward P/E|Sionna Therapeutics, Inc. (SION) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Prime Medicine, Inc.|QURE - Pangali forward rega marang bathi|Pangali Forward P/E MGTX|Kapitalisasi marang proyeksi bathi regenxbio.com|Pangali Forward P/E SLDB (Solid Biosciences Inc)|OCGN: Rasio rega marang bathi mangsa ngarep|PACB - Rega marang bathi mangsa ngarep|Benitec (BNTC) - Prakiraan rega marang bathi|DSGN: Pangali Forward P/E|RCKT: Rasio kapitalisasi marang bathi mangsa ngarep|FDMT (4D Molecular Therapeutics, Inc.) - Pangali Forward P/E|lexeotx.com (LXEO) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E KRRO|Prakiraan rega marang bathi Editas Medicine, Inc. EDIT|Rega marang bathi mangsa ngarep silence-therapeutics.com SLN|PRQR: Rasio rega marang bathi mangsa ngarep|CDXS - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi Metagenomi, Inc. (MGX)|Prakiraan rega marang bathi DTIL|Rasio rega marang bathi mangsa ngarep GBIO (generationbio.com)|Rega marang bathi mangsa ngarep Boundless Bio, Inc (BOLD)|Pangali Forward P/E Exicure Inc. (XCUR)|Imunon, Inc. - Prakiraan rega marang bathi|PHIO: Rasio rega marang bathi mangsa ngarep|MBIO - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake RNAZ|Bionano Genomics, Inc. (BNGO) - Rega marang bathi mangsa ngarep|Applied DNA Sciences, Inc. (APDN) - Pangali Forward P/E|BLUE (bluebirdbio.com) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise Antibodies)|Pangali Forward P/E OMGA|Prakiraan rega marang bathi Singular Genomics Systems OMIC|Pangali Forward P/E RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Rasio prakiraan rega marang bathi|TBIO: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi TCON (TRACON)|UBX: Pangali Forward P/E